Abstract Cyclin-dependent kinase 5 (CDK5) is the serine/threonine-directed kinase mainly
found in the brain and plays a significant role in developing the central nervous system …

Recent studies have uncovered various physiological functions of CDK5 in many
nonneuronal tissues. Upregulation of CDK5 and/or its activator p35 in neurons promotes …

Background Hepatocellular carcinoma (HCC) remains difficult to treat due to limited effective
treatment options. While the proteasome inhibitor bortezomib has shown promising …

Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent monogenic
human disease, but to date, only one therapy (tolvaptan) is approved to treat kidney cysts in …

Simple Summary The proteasome inhibitor bortezomib is currently commonly used for the
treatment of multiple myeloma (MM). MicroRNAs (miRNAs) are small non-coding RNAs that …

Currently, multiple myeloma is not yet considered a curable disease. Despite the recent
advances in therapy, the average patient lifespan is still unsatisfactory. Recently, CDK9 …

Simple Summary The mRNA expression of nine previously described genes that may affect
resistance to multiple myeloma (MM), viz., ABCB1, CXCR4, MAF, MARCKS, POMP, PSMB5 …

Abstract Cyclin‐dependent kinase 5 (Cdk5) is a protein expressed in postmitotic neurons in
the central nervous system (CNS). Cdk5 is activated by p35 and p39 which are neuron …

Alzheimer's disease (AD) remains one of the most challenging and prevalent
neurodegenerative disorders worldwide. Despite extensive research efforts, effective …

Abstract Proteasome inhibitors (PIs), bortezomib, carfilzomib, and ixazomib, are the first-line
treatment for multiple myeloma (MM). They inhibit cytosolic protein degradation in cells …